Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors

• US 5,652,236 A
• Filed: 02/27/1996
• Issued: 07/29/1997
• Est. Priority Date: 12/08/1994
• Status: Expired due to Fees

• Current Assignee: Allergan SPA (Abbvie Incorporated)
• Original Assignee: Allergan SPA (Abbvie Incorporated)
• Inventors: Krauss, Achim H.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US08/607,744
• Time in Patent Office: 518 Days
• Field of Search: 514/227.5, 514/912, 514/913
• US Class Current: 514/227.5
• CPC Class Codes: A61K 31/085 having an ether linkage to aromatic ring nuclear carbon
• CPC Class Codes: A61K 31/131 acyclic
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/5415 ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam

Abstract

Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having guanylate cyclase inhibition activity. Examples of guanylate cyclase inhibitors utilized in the pharmaceutical composition and method of treatment are methylene blue, butylated hydroxyanisole and N-methylhydroxylamine.

Claims

1. A method of treating animals of the mammalian species, including humans, for the purpose of reducing intraocular pressure in the eye of the mammal, comprising the step of administering to the mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having guanylate cyclase inhibition activity, wherein said compound having guanylate cyclase inhibition activity is selected from the group consisting of methylene blue, butylated hydroxyanisole, N-methyl hydroxylamine and pharmaceutically acceptable salts thereof.

2. The method of treatment of claim 1 where the composition is an ophthalmic solution adapted for administration to the eye of a mammal in the form of eye droplets.

3. The method of treatment of claim 2 where the ophthalmic composition the concentration of the compound having guanylate cyclase inhibition activity is in the range of approximately 0.0001 to 1.0 per cent weight by volume.

4. A method for providing neuroprotective effect to the eye of a mammal which comprises the step of administering to the mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having guanylate cyclase inhibition activity, wherein said compound having guanylate cyclase activity is selected from the group consisting of methylene blue, butylated hydroxyanisole, N-methyl hydroxyl amine and pharmaceutically acceptable salts thereof.

5. The method of claim 4 wherein the composition contains approximately 0.0001 to 1.0 per cent weight by volume of said compound having guanylate cyclase inhibition activity.